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Abstract
Background: The interplay between IFN-γ, IL-17 and neutrophils during CNS inflammatory disease is complex due
to cross-regulatory factors affecting both positive and negative feedback loops. These interactions have hindered
the ability to distinguish the relative contributions of neutrophils, Th1 and Th17 cell-derived effector molecules from
secondary mediators to tissue damage and morbidity.
Methods: Encephalitis induced by a gliatropic murine coronavirus was used as a model to assess the direct
contributions of neutrophils, IFN-γ and IL-17 to virus-induced mortality. CNS inflammatory conditions were
selectively manipulated by adoptive transfer of virus-primed wild-type (WT) or IFN-γ deficient (GKO) memory CD4+
T cells into infected SCID mice, coupled with antibody-mediated neutrophil depletion and cytokine blockade.
Results: Transfer of GKO memory CD4+ T cells into infected SCID mice induced rapid mortality compared to
recipients of WT memory CD4+ T cells, despite similar virus control and demyelination. In contrast to recipients of
WT CD4+ T cells, extensive neutrophil infiltration and IL-17 expression within the CNS in recipients of GKO CD4+ T
cells provided a model to directly assess their contribution(s) to disease. Recipients of WT CD4+ T cells depleted of
IFN-γ did not express IL-17 and were spared from mortality despite abundant CNS neutrophil infiltration, indicating
that mortality was not mediated by excessive CNS neutrophil accumulation. By contrast, IL-17 depletion rescued
recipients of GKO CD4+ T cells from rapid mortality without diminishing neutrophils or reducing GM-CSF, associated
with pathogenic Th17 cells in CNS autoimmune models. Furthermore, co-transfer of WT and GKO CD4+ T cells
prolonged survival in an IFN-γ dependent manner, although IL-17 transcription was not reduced.
Conclusions: These data demonstrate that IL-17 mediates detrimental clinical consequences in an IFN-γ-deprived
environment, independent of extensive neutrophil accumulation or GM-CSF upregulation. The results also suggest
that IFN-γ overrides the detrimental IL-17 effector responses via a mechanism downstream of transcriptional
regulation.
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Background
IL-17 and IFN-γ play diverse and often opposing func-
tions during microbial infections, as well as autoimmune
diseases. These interactions are partially attributed to
their distinct regulation of the neutrophil response. Both
IL-17A and IL-17 F signal through the IL-17R to induce
granulocyte colony-stimulating factor and stem cell
factor, thereby expanding neutrophil progenitors in the
bone marrow and spleen as well as increasing mature
neutrophils in the blood [1-3]. IL-17 also induces ELR+
CXC chemokines, which attract neutrophils [2,3]. By
contrast, IFN-γ opposes neutrophil recruitment by
downregulating expression of neutrophil chemoattrac-
tants [4]. Analysis of polarized T cell subsets and genet-
ically deficient mice has provided insight into the
distinct effector functions of IL-17 and IFN-γ; however,
the interplay between IL-17 and IFN-γ in vivo remains
complex [5,6]. Moreover, downstream effector mechanisms
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mediating pathological consequences may be tissue- and
pathogen-specific and are largely unresolved. For example,
Th17 cell-mediated protection is critical during bacterial
pneumonia [2]. IL-17-mediated neutrophil recruitment to
the infection site also indicates a protective role for Th17
cells during oropharyngeal candidiasis [7]. By contrast,
Th17-mediated inhibition of both protective Th1 responses
and antimicrobial neutrophil functions increased tissue de-
struction following gastric candidiasis and pulmonary as-
pergillosis [8]. These differences may reflect distinct
infection sites, as indicated by the distinct immune
responses to Candida albicans, which are dependent upon
the anatomical site of infection [7].
Viral infections are often dominated by Th1 responses.
However, the coemergence of Th17 and Th1 cells has
recently been documented in several infections, includ-
ing human immunodeficiency virus [9], simian immuno-
deficiency virus [10] and cytomegalovirus [11]. A
deleterious role of IL-17 is implied by acute lung injury
associated with IL-17-mediated neutrophil recruitment
during influenza virus infection [12]. By contrast, Th17
responses are protective against lethal influenza virus in-
fection in IL-10-deficient mice [13]. Similarly, IFN-γ-
mediated protection during herpes simplex virus-1 cor-
neal infection correlated with reduced IL-17 production
and subsequent neutrophil infiltration [14]. However,
the function of IL-17 during central nervous system
(CNS) viral infections, including human immunodefi-
ciency virus encephalitis, is unclear, although Th17 cells
promote Theiler’s murine encephalomyelitis virus per-
sistence and chronic demyelination by limiting the anti-
viral cytotoxic T-lymphocyte response [15].
In contrast to the limited information on IL-17 func-
tion during viral encephalitis, analysis of experimental
autoimmune encephalitis (EAE) has revealed numerous
insights into effector mechanisms as well as crosstalk be-
tween Th1 and Th17 cells [16]. Although the inflamma-
tory CNS disease multiple sclerosis and its animal model
EAE were historically associated with a Th1 immune re-
sponse [17,18], a pro-inflammatory role of IFN-γ was
contradicted by substantially increased disease severity
and mortality in mice deficient in IFN-γ (GKO) or the
IFN-γR [19,20]. The correlation between increased EAE
severity, enhanced Th17 responses and neutrophil infil-
tration into the CNS of GKO mice suggested that IFN-γ
might be protective by inhibiting the Th17 response
[21]. Although IL-17−/− mice are susceptible to EAE
[22], adoptive transfer of polarized encephalitogenic
CD4+ T cells support Th17 cells as detrimental partici-
pants in EAE [23,24]. However, the pathogenic mechan-
isms associated with Th17 cells remain an ongoing
challenge and may involve multiple pathways. These in-
clude excessive CNS neutrophil infiltration and release
of degrading enzymes, free radicals and pro-inflammatory
cytokines, direct IL-17-mediated neuronal toxicity [25],
and/or secretion of granulocyte macrophage colony-
stimulating factor (GM-CSF) as the pathogenic effector
molecule [26-28]. These data suggest that the balance be-
tween IFN-γ and IL-17 effector functions, as well as their
regulation of neutrophils may dictate the outcome of
non autoimmune-driven CNS inflammation, such as viral
encephalitis.
During encephalomyelitis induced by the strain desig-
nated JHMV, CD4+ T cells not only contribute to anti-
viral effects by enhancing CD8+ T cell function within
the CNS [29] but also mediate viral control in absence
of CD8+ T cells [30]. Nevertheless, they also contribute
to both clinical disease and demyelination [30]. To de-
fine the role of CD4+ relative to CD8+ T cells in viral en-
cephalitis, memory CD4+ T cells from immunized
donors were transferred into infected severe combined
immunodeficiency (SCID) mice [31]. This study revealed
an early morbidity and mortality in infected recipients of
CD4+ T cells lacking the ability to secrete IFN-γ com-
pared to recipients of IFN-γ-sufficient CD4+ T cells or
infected unreconstituted control mice [31]. Notably,
both memory populations were equally effective in con-
trolling virus replication [31]. The lethal outcome was
specific for CD4+ T cells lacking IFN-γ [31], but not for
a similar memory CD8+ T cell population deficient in
IFN-γ [32]. These data suggest that mortality was related
to immune effector functions specific to CD4+ T cells
and controlled by IFN-γ.
In this study, SCID recipients of GKO CD4+ T cells
infected with JHMV were characterized by extensive
neutrophil accumulation and IL-17 expression within
the CNS. Neutrophil infiltration in the absence of IFN-γ
correlated with significantly elevated levels of CXCL1,
independent of IL-17. Moreover, comparison of infected
recipients of wild-type (WT) CD4+ T cells depleted of
IFN-γ and recipients of GKO CD4+ T cells depleted of
IL-17 revealed mortality was due to IL-17, irrespective
of abundant neutrophil accumulation. IFN-γ introduced
by co-transfer of WT CD4+ T cells with IL-17-producing
GKO CD4+ T cells abrogated the detrimental effects of
IL-17 without affecting IL-17 transcription within the
CNS. These data thus segregate the effects of toxic neu-
trophil components from IL-17-mediated pathogenesis.
Material and Methods
Mice
Homozygous BALB/c Thy1.1 mice, provided by Dr. J. Harty
(University of Iowa, Iowa City, IA, USA) and GKO
BALB/c mice, provided by Dr. R. Coffman (DNAX Re-
search, Palo Alto, CA, USA), were bred locally at the
Cleveland Clinic. SCID mice were obtained from the Na-
tional Cancer Institute (Frederick, MD, USA). Recipients
and donors were maintained under sterile conditions
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and all procedures were performed in compliance with
Cleveland Clinic Institutional Animal Care and Use
Committee-approved protocols.
Virus
The gliatropic JHM strain of mouse hepatitis virus
(JHMV)-neutralizing mAb variant designated 2.2v-1 was
used for intracerebral infection [33]. JHMV was propa-
gated and plaque assayed on monolayers of DBT cells, a
continuous murine astrocytoma cell line [32]. SCID mice
were injected in the left hemisphere with 30 μl volume
containing 500 PFU of JHMV diluted in endotoxin-free
Dulbecco’s modified PBS. The severity of the JHMV-
induced clinical disease was graded as follows: 0, healthy;
1, ruffled fur and hunched back; 2, partial hind limb par-
alysis or inability to turn to the upright position; 3,
complete hind limb paralysis; 4, moribund or dead.
Virus titers were determined on plaque assay on mono-
layers of DBT cells as previously described [32,33].
Briefly, brains were homogenized in ice-cold Dulbecco’s
PBS using Ten Broeck tissue homogenizers (Kimble
Chase, Vineland, NJ, USA). After clarification by centri-
fugation at 400 x g for 7 minutes at 4°C, supernatants
were stored at −70°C whereas pellets containing CNS-
derived cells were suspended in Percoll (GE Healthcare
Bio-Sciences AB, Uppsala, Sweden) and used for flow
cytometry analysis (see below).
T cell purification and adoptive transfer
BALB/c Thy1.1 and GKO donors were immunized by
intraperitoneal (i.p.) injection with 2 × 106 PFU of JHMV.
Donor splenocytes were prepared four to sixteen weeks
post immunization. CD4+ T cells were purified by posi-
tive selection using anti-CD4-coated magnetic beads
(Miltenyi Biotec Inc., Auburn, CA, USA). Purity of the
purified population was assessed by flow cytometry
using fluorescein isothiocyanate- (FITC) labeled anti-
CD4 (clone GK1.5), phycoerythrin- (PE) labeled anti-
CD8 (clone 53-6.7) and peridinin chlorophyll protein-
(PerCP) labeled anti-CD19 (clone 1D3) mAbs (BD Phar-
mingen, San Diego, CA, USA). Recipients received
5 × 106 donor CD4+ T cells composed of 100% Thy1.1
(WT), 100% GKO or a 50/50% mixture of Thy1.1/GKO
(WT/GKO) CD4+ T cells by intravenous (i.v.) injection
coupled with a single i.p. injection of 250 μg of anti-CD8
mAb (clone TIB.210). Mice were challenged with virus
two to three hours after adoptive transfer. For neutrophil
depletion, mice received i.p. injections of either 500 μg
of anti-Ly-6G (clone 1A8) or anti-Gr1 (clone RB6-8C5)
mAb every other day until sacrifice, starting two days
before infection. Depletion was confirmed in both cases
by flow cytometric analysis using anti-Ly-6G (clone 1A8)
mAb in addition to examination of hematoxylin and
eosin- (H&E) stained sections of brain. Only data for the
anti-Ly6G experiments are shown. No differences in sur-
vival relative to control-treated mice were observed fol-
lowing treatment with either neutrophil-depleting mAb.
Similarly, for anti-IFN-γ treatment, mice received i.p.
injections of 500 μg of anti-IFN-γ (clone XMG1.2) mAb
every other day, starting two days before infection. For
anti-IL17 treatment, mice received i.p. injections of 1 mg
of anti-IL-17A (clone 1D10) mAb at day zero and six
post infection (p.i.).
Isolation of central nervous system-derived cells
After brain homogenization and centrifugation to obtain
supernatants for virus determination as described above,
cell pellets were resuspended in RPMI containing 25
mM HEPES, pH 7.2 and adjusted to 30% Percoll (GE
Healthcare Bio-Sciences BA). A 1 ml underlay of 70%
Percoll was added prior to centrifugation at 800 x g for
30 minutes at 4°C. Cells were recovered from the 30% to
70% interface and washed with RPMI medium prior to
analysis.
Flow cytometry
CNS mononuclear cell suspensions were blocked with
anti-mouse CD16/CD32 (clone 2.4G2, BD Pharmingen)
mAb on ice for 15 minutes prior to staining. Cells were
then stained with FITC-, PE-, PerCP- or allophycocyanin-
conjugated mAb for 30 minutes on ice in PBS containing
0.1% BSA. Expression of surface molecules was character-
ized using the following mAbs (all obtained from BD
Pharmingen except when indicated): anti-CD45 (Clone
Ly-5), anti-CD4 (clone GK1.5), anti-Thy1.1 (clone OX-7),
anti-CD8 (clone 53-6.7), anti-CD11b (clone M1/70), anti-
F4/80 (Serotec, Oxford, UK), anti-Ly6G (clone 1A8) and
anti I-A/I-E (clone 2G9). Samples were analyzed on a
FACSCalibur flow cytometer using CellQuest software
(Becton Dickinson, Mountain View, CA, USA).
Gene expression analysis
RNA was isolated from three or more individual brains per
group using TRIzoL reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. cDNAs
were prepared using SuperScript II Reverse Transcriptase
(Invitrogen) and oligo (dT)12–18 primers (Invitrogen). Semi-
quantitative RNA expression was assessed using Light-
Cycler and SYBR Green kit (Roche, Basel, Switzerland) and
the following primers; ubiquitin: F: 5’- TGGCTATTAAT-
TATTCGGTCTGCAT-3’, R: 5’- GCAAGTGGCTAGAGT
GCAGAGTAA -3’; IFN-γ: F: 5’- TGATGGCCTGATTGTC
TTTCAA-3’, R: 5’- GGATATCTGGAGGAACTGGCAA-
3’; IL-17: F: 5’-CTTCATCTGTGTCTCTGATGCTGTT-3’,
R: 5’- TCGCTGCTGCCTTCACTGT-3’; IL-22: F: 5’- CAT
GCAGGAGGTGGTACCTT-3’, R: 5’- CAGACGCAAGC
ATTTCTCAG-3’; IL-21: F: 5’- GGACAGTATAGACGCT
CACGAATG-3’, R: 5’- CGTATCGTACTTCTCCACTT
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GCA-3’; MHC class II: F: 5’- TCAACATCACATGGCT
CAGAAATA-3’, R: 5’- AGACAGCTTGTGGAAGGAA
TGG-3’; GM-CSF: F: 5’- TTTCCTGGGCATTGTGGT
CTA -3’, R: 5’- AAGGCCGGGTGACAGTGAT -3’; IL-6: F:
5’- ACACATGTTCTCTGGGAAATCGT -3’, R: 5’- AAG
TGCATCATCGTTGTTCATACA-3’; IL-1β: F: 5’- GACG
GCACACCCACCCT-3’, R: 5’- AAACCGTTTTTCCAT
CTTCTTCTTT-3’; CCL7: F: 5’-GGGAAGCTGTTATCT
TCAAGACAAA-3’, R:5’-CTCCTCGACCCACTTCTGA
TG-3’; CCL20: F: 5’-GGTGGCAAGCGTCTGCTC-3’, R:
5’-GCCTGGCTGCAGAGGTGA-3’; CXCL2: F: 5’-CCTG
CCAAGGGTTGACTTCA-3’, R: 5’-TTCTGTCTGGGC
GCAGTG-3’; MMP9: F: 5’- CCATGCACTGGGCTTAG
ATCAT-3’, R: 5’- CAGATACTGGATGCCGTCTATGTC-
3’; MMP3: F: 5’- TTTAAAGGAAATCAGTTCTGGGC
TATA-3’, R: 5’-CGATCTTCTTCACGGTTGCA-3’; M
MP12: F: 5’- GGAGCTCACGGAGACTTCAACT-3’, R: 5’-
CCTTGAATACCAGGTCCAGGATA -3’. TaqMan primers
and 2X TaqMan fast master mix (Applied Biosystems,
Carlsbad, CA, USA) were used to assessed CXCL1 and
CCL2 mRNA levels. Levels of mRNA expression were nor-
malized to ubiquitin mRNA using ΔCt method as previ-
ously described [31].
Immunofluorescence
After ice-cold PBS perfusion, brains in OCT were frozen
in liquid nitrogen and stored at −80°C until 10 μm sec-
tions were prepared. Sections were fixed with methanol/
acetone (1:1 ratio) for 15 minutes and then treated with
blocking solution for 30 minutes at room temperature.
Rat anti-mouse IL-17 (R&D systems, Minneapolis, MN,
USA) and hamster anti-mouse CD3 primary mAbs (Ser-
otec) were incubated overnight at 4°C. Alexa Fluor 488
goat anti-rat (Invitrogen) and Alexa Fluor 546 goat anti-
hamster (Molecular Probes, Eugene, OR, USA) were
added for 1 hour at room temperature. Sections were
mounted with Vectashield mounting medium with 4’-6-
Diamidino-2-phenylindole (DAPI) (Vector Laboratories,
Burlingame, CA, USA) and analyzed using a Leica
DM4000B fluorescent microscope (Leica, Wetzlar,
Germany).
In vitro T cell stimulation
Cytokine expression by CD4+ T cells derived from cer-
vical lymph nodes of SCID recipients were analyzed dir-
ectly at day eight p.i. without stimulation with viral
antigen. For analysis of cytokine production by cells
prior to transfer, JHMV was adsorbed to donor spleno-
cytes for 60 minutes at 4°C and cells cultured for six
days in RPMI complete, 10% FCS at 2.5 × 106 cells/ml.
Cytokine production from both splenic cultures or
ex vivo lymph node cells was measured following four
hours stimulation with PMA (10 ng/ml) (Acros Organ-
ics, Geel, Belgium) and ionomycin (1 μM) (Calbiotech,
Spring Valley, CA, USA). Monensin (2 μM) (Calbiotech)
was added to the cultures for the last two hours. After
stimulation, cells were harvested and stained for surface
expression of CD4. Cells were then permeabilized using
the cytofix/cytoperm kit (BD Pharmingen) according to
the manufacturer’s instructions and stained for intracel-
lular FITC-IFN-γ and PE-IL-17.
Statistical analyses
Statistical differences were calculated using the two-
tailed unpaired Student’s t-test. P values <0.05 were
considered significant. *p< 0.05, **p< 0.01, ***p< 0.001.
Results
IFN-γ mediated control of central nervous system
neutrophil infiltration is not the sole factor regulating
survival
One characteristic of GKO CD4+ T cell recipients
infected with JHMV was the large CNS infiltrating neu-
trophil population (72.3% compared to 17.5% in WT
CD4+ T cells recipients) (Figure 1A) [31]. Increased neu-
trophil accumulation in GKO recipients is consistent
with IFN-γ-mediated downregulation of ELR+ neutrophil
chemokines [4]. Indeed, analysis of cytokine and chemo-
kine mRNA expression in infected T cell recipients
demonstrated that high IFN-γ mRNA correlated in-
versely with mRNA expression of the neutrophil chemo-
attractant CXCL1 (Figure 1B). Thus, IFN-γ mRNA in
WT CD4+ T cell recipients was associated with sparse
CXCL1 expression and neutrophil recruitment, while
low IFN-γ mRNA expression in both GKO CD4+ T cell
recipients and infected SCID controls correlated with
high CXCL1 expression and extensive neutrophil re-
cruitment. Infected mice were depleted of neutrophils to
explore a possible correlation between neutrophil-
derived proteases, free radicals and proinflammatory
cytokines with virus-induced mortality. Depletion was
confirmed by the absence of Ly6G+ CD11b+ neutrophils
within the CNS-derived inflammatory cells (Figure 1C).
However, the absence of neutrophils did not prevent
early mortality of GKO CD4+ T cell SCID recipients
(Figure 1C), implicating alternate mechanisms inducing
mortality in GKO recipients.
In contrast to memory GKO CD4+ T cells derived
from JHMV-immunized donors, memory GKO CD8+ T
cells did not trigger early mortality in infected SCID
recipients [32]. These data suggest that IFN-γ deficiency
was not the sole factor controlling early death. WT CD4+
T cell recipients were depleted of IFN-γ to confirm
that a CD4+ T cell factor distinct from IFN-γ controls
disease outcome. The modestly reduced survival rate of
IFN-γ-depleted WT CD4+ T cell recipients (Figure 2A)
demonstrated IFN-γ blockade did not reproduce the
mortality of GKO CD4+ T cell recipients. The efficiency
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of IFN-γ blockade within the CNS was confirmed by ana-
lyzing IFN-γ-dependent MHC class II expression on
microglia [34]. In contrast to class II expression on the
vast majority of microglia in recipients of WT CD4+ T
cells, class II remained undetectable in anti-IFN-γ-trea-
ted WT recipients (Figure 2B), confirming inhibition of
local IFN-γ signaling within the CNS. IFN-γ depletion
also had minimal effects on T cell recruitment into the
CNS, reducing the CD4+ T cells within the inflammatory
population from 15.4% to 12.3% (data not shown). In
support of the role of IFN-γ in regulating neutrophils,
IFN-γ-depleted WT recipients exhibited vastly increased
CNS neutrophil infiltration, approaching the numbers
found in GKO CD4+ T cell recipients (Figure 2C). In
addition to confirming IFN-γ-mediated control of CNS
neutrophil recruitment [4], these data reassert that abun-
dant CNS neutrophils are insufficient to account for early
mortality.
IL-17 mediates mortality, independent of neutrophils
Neither IL-6 nor IL-1β, whose over expression is asso-
ciated with adverse effects on the CNS [35,36], were
increased in the CNS of GKO compared to WT CD4+ T
cell recipients (Figure 3A). Previous data demonstrated
that TNF and inducible nitric oxide synthase were also
not associated with early mortality of GKO recipients
[31]. Indeed, passive transfer of neutralizing anti-TNF
mAb was unable to alter the mortality of the GKO CD4+
Figure 1 Neutrophil depletion does not prevent early mortality. (A) Neutrophil infiltration was characterized by flow cytometry based on
CD45hi Ly6G+ expression (R4 region) in the CNS of controls (control (ctr); infected SCID mice without CD4+ T cell transfer), infected SCID
recipients of WT (WT) or GKO CD4+ T cells (GKO) eight days p.i. (B) Mean expression (±SEM) of IFN-γ and CXCL1 mRNA analyzed in brains of
naïve (n = 4), controls (n = 3), SCID recipients of WT (n = 4) or GKO (n = 4) CD4+ T cells at day eight p.i. Data are representative of two experiments.
(C) Survival rates of SCID recipients of WT or GKO CD4+ T cells (with and without neutrophil depletion) observed daily following JHMV infection.
Data represent the mean of sixteen mice per group combined from two separate experiments with n = 8 per group in each experiment.
Efficiency of neutrophil (CD45hi Ly6G+, R4 region) depletion after antibody (Ab) treatment analyzed by flow cytometry in the CNS of SCID
recipients of GKO CD4+ T cells at day eight p.i. Density plots are representative of eight animals per group.
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Figure 2 Anti-IFN-γ induced CNS neutrophil infiltration but did not increase mortality in SCID recipients of WT CD4+ T cells. (A) Survival
of infected SCID recipients of WT CD4+ T cells in the absence or presence of anti-IFN-γ mAb and recipients of GKO CD4+ T cells assessed daily
until day ten p.i. Data are mean of at least six mice per group combined from two separate experiments (B) Anti-IFN-γ mAb efficiency assessed
by flow cytometry by measuring MHC class II expression on microglia (CD45lo F4/80+) in infected SCID recipients of WT (n = 6), WT+ anti-IFN-γ
mAb (n = 8) or GKO (n = 8) CD4+ T cells. Data are representative of two experiments. (C) Numbers of infiltrating neutrophils in the brain of
infected SCID recipients of WT, WT+ anti-IFN-γ mAb or GKO CD4+ T cells determined by flow cytometry at day eight p.i. Data represent the mean
(±SD) from two independent experiments (n = 6, untreated group and n= 8, anti-IFN-γ treated group).
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Figure 3 IL-17 expression in SCID recipients of GKO CD4+ T cells. IL-6 and IL-1β (A), IL-17 (B), and IL-22 and IL-21 (C) mRNA expression
analyzed by quantitative real-time PCR in brains of naïve (n= 4), infected control (n= 3), infected SCID recipients of WT (n= 4) or GKO (n=8) CD4+ T
cells at day eight p.i. IL-17 mRNA expression was measured in infected SCID recipients of WT CD4+ T cells + anti-IFN-γ mAb (n=8). Data represent the
mean (±SEM) from two separate experiments. (D) IL-17 (green) and CD3 (red) expression in the brains of SCID recipients of GKO CD4+ T cells. CD3+
(arrows) and IL-17-producing T cells (arrow heads) detected at day eight p.i. (E) IL-17-expressing CD4+ T cells from cervical lymph nodes of SCID
recipients of GKO CD4+ T cells at day eight p.i. Dot plots are representative of four individuals. (F) Expression of IFN-γ and IL-17 by donor-derived CD4+
T cells prior to transfer analyzed by flow cytometry after in vitro stimulation. Intracellular cytokine expression measured using FITC-IFN-γ, PE-IL-17 and
the corresponding isotype controls. Dot plots are representative of duplicates from two separate experiments. N.D = Not Detected.
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T cell recipients (data not shown). These results sug-
gested additional factor(s) intrinsic to GKO CD4+ T cells
in mediating disease outcome. Inhibition of IL-17 pro-
duction by IFN-γ [37], suggested IL-17 as a potential
candidate. Consistent with this concept, IL-17 mRNA
expression was increased in the CNS of GKO CD4+ T
cell recipients (Figure 3B), although IL-17 is not
expressed in the CNS of infected WT mice [38]. Import-
antly, IL-17 mRNA remained below detection not only
in SCID-infected control mice lacking T cells, but also in
recipients of WT CD4+ T cells depleted of IFN-γ
(Figure 3B), both of which are characterized by vast
CNS neutrophil infiltration (Figure 1A). Although
neutrophil-derived IL-17 has been implicated in enhan-
cing tissue damage during reperfusion injury [39], these
data suggest that neutrophils recruited into the CNS do
not secrete IL-17 during acute viral encephalitis. Expres-
sion of IL-17 mRNA only in GKO CD4+ T cell recipients
also ruled out a potential contribution of resident CNS
cells. IL-17 expression exclusively in the CNS of GKO
recipients thus implied that the source of IL-17 was the
GKO-derived CD4+ T cell population itself. In support
of this concept, transcript levels encoding IL-22, another
cytokine produced by Th17 cells [40], were also signifi-
cantly increased in infected GKO recipients compared
to WT recipients and infected SCID control mice
(Figure 3C). By contrast, IL-21, a CD4+ T cell-derived
cytokine known to provide helper functions to CD8+ T
cells and B cells [41] was expressed at similar levels in
both the GKO and WT CD4+ T cell recipient groups
(Figure 3C). IL-17 production by CD4+ T cells in the
CNS of GKO recipients was confirmed by immunofluor-
escence histochemistry. A substantial fraction of T cells
within the CNS of GKO recipients expressed IL-17.
Moreover, all IL-17 positive cells co-expressed CD3
(Figure 3D), indicating that T cells are the predominant
source of IL-17 within the CNS of SCID recipients. In
contrast to the CNS, only ~8% of T cells in the cervical
lymph nodes of GKO recipients secreted IL-17 at day
eight p.i. (Figure 3E), suggesting enrichment of IL-17-
expressing T cells within the CNS. To determine if IL-17
expression is imprinted during the primary response fol-
lowing immunization of GKO donor mice, cytokine ex-
pression was analyzed in the memory WT and GKO T
cell populations prior to transfer (Figure 3F). WT mem-
ory CD4+ T cells prominently expressed IFN-γ and very
little, if any, IL-17 following in vitro stimulation. By con-
trast, immunization of GKO mice primed a small fraction
of memory CD4+ T cells capable of producing IL-17.
These results were consistent with IFN-γ-mediated inhib-
ition of Th17 cells [42] and suggested that IL-17 expres-
sion was imprinted prior to transfer and re-expressed in
the infected recipients. To confirm a role of IL-17 in the
early mortality of GKO recipients, WT and GKO
recipients were treated with anti-IL-17 mAb. Consistent
with the absence of IL-17 mRNA in the CNS of the WT
recipients, anti-IL-17 treatment had no effect on the sur-
vival of WT recipients (Figure 4A). By contrast, inhibition
of IL-17 in GKO recipients lead to a significant decrease
in mortality, with 73% of mice surviving to day 18 p.i.
(Figure 4A). In support of the concept that mortality was
not influenced by neutrophils, the increased neutrophil in-
filtration in the CNS of GKO recipients was not altered by
anti-IL-17 treatment (Figure 4B), confirming their pri-
mary regulation by IFN-γ [4].
IFN-γ overcomes IL-17-derived CD4+ T cell mediating
mortality
Cross-regulation of IFN-γ and IL-17 in shaping CD4+ T
cell subsets is well established during primary T cell acti-
vation and expansion [43,44]; however, less is known
about cross-regulation during antigen-induced restimu-
lation of memory T cells. IL-23 has recently been shown
to promote GM-CSF expression by Th17 cells, which in
turn enhances detrimental disease outcomes [27,28].
Based on the observation that GM-CSF is downregu-
lated by IFN-γ [27], we tested whether IFN-γ-producing
CD4+ T cells can override the detrimental function of
GKO CD4+ T cell-mediated IL-17 expression. Memory
CD4+ T cells from WT Thy1.1 immunized mice were
co-transferred with Thy1.2 GKO CD4+ T donor cells
(WT/GKO recipients) prior to infection. MHC class II
expression was measured in the CNS of all recipient
groups to confirm functional IFN-γ expression [34].
Class II mRNA was maximal in the CNS of WT recipi-
ents, reaching 22-fold higher levels than in GKO recipi-
ents. MHC class II mRNA was increased 10-fold
following the co-transfer of WT and GKO CD4+ T cells
compared to mice receiving GKO CD4+ T cells alone
(Figure 5A). Increased mRNA expression correlated with
MHC class II protein expression by the majority of
microglia in both WT and co-transfer groups (Figure 5A).
Although the proportion of microglia expressing MHC
class II was decreased in the co-transfer compared to the
WT groups, differences were not statistically significant
(Figure 5A). Co-transfer of WT and GKO CD4+ T cells
protected recipients from early mortality (Figure 5B).
Disease severity was similar in WT and WT/GKO recipi-
ents and significantly reduced compared to GKO-only
recipients, especially after day six p.i. (data not shown). In
addition, control of CNS virus replication was identical
at day eight p.i. in recipients of WT, WT/GKO or GKO
CD4+ T cells (Figure 5C), confirming previous results
that accelerated mortality does not correlate with uncon-
trolled virus replication [31]. CNS leukocyte infiltration
in WT/GKO CD4+ T cell recipients was similar to WT
recipients, and lower than GKO recipients (Figure 5D).
Specifically, neutrophils within CD45hi bone-marrow-
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derived inflammatory cells were reduced to 16% in WT/
GKO recipients, resembling the proportion in WT recipi-
ents (Figure 5D and data not shown).
Overall these data confirm IFN-γ-mediated control of
CNS neutrophil infiltration and suggested a protective
role of IFN-γ during viral encephalitis, via inhibiting IL-
17 effector function by either directly reducing Th17 cell
expansion and/or CNS entry, or limiting GM-CSF pro-
duction. To assess whether GKO CD4+ T cells migrated
to the CNS in the presence of WT CD4+ T cells, the
relative proportions of each donor population was exam-
ined by co-transfer of Thy1.1 WT CD4+ T cells and
Thy1.2 GKO CD4+ T cells. Surprisingly, T cells recruited
into the CNS of infected co-transferred recipients were
essentially derived from the GKO memory CD4+ T cells,
as less than 20% of CD4+ T cells expressed Thy1.1+
(Figure 6A). Given the large population of infiltrating
GKO CD4+ T cells, we next determined if IFN-γ-
mediated protection correlated with reduced IL-17
mRNA expression. Although protective, the minor
population of WT CD4+ T that infiltrated the CNS did
not reduce expression of IL-17 mRNA in the CNS
(Figure 6B). Protection mediated by IFN-γ, despite ele-
vated IL-17, suggested that IFN-γ interferes with IL-17-
mediated signaling events, rather than directly influen-
cing Th17 expression. This notion was tested by in vitro
stimulation of memory CD4+ T cells derived from GKO
donors in the presence of recombinant IFN-γ. Exogen-
ous IFN-γ was indeed unable to downregulate IL-17
production (Figure 6C), supporting the in vivo observa-
tion that IFN-γ-expressing WT CD4+ T cells did not
alter CNS expression of IL-17 mRNA in WT/GKO reci-
pients (Figure 6B). The maintenance of IL-17 in the
presence of IFN-γ in vitro and in vivo indicates that the
phenotypes acquired during in vivo primary responses
are retained in the transferred memory cells following
reactivation in recipient mice. To confirm this assump-
tion, IFN-γ was depleted in WT/GKO recipients. WT/
GKO recipients treated with anti-IFN-γ succumbed to
infection by day nine p.i. similar to infected recipients of
Figure 4 IL-17 mediates mortality, independent of CNS neutrophil infiltration. (A) Survival was assessed daily in infected SCID recipients of
WT (n = 8), WT+ anti-IL-17 mAb (n= 12), GKO (n = 8) and GKO+ anti-IL-17 mAb (n = 12) CD4+ T cells until day 18 p.i. Data are mean from two
separate experiments (B) Total numbers of neutrophils determined by flow cytometry at day eight p.i. in infected SCID recipients of WT,
WT+ anti-IL-17 mAb, GKO, GKO+ anti-IL-17 mAb CD4+ T cells. Data represent the mean from two independent experiments (n = 4, untreated
mice and n= 8, anti-IL-17-treated mice per experiment).
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GKO CD4+ T cell (Figure 6D). These data actually sug-
gest that IFN-γ diminishes the detrimental effects of IL-
17, despite the apparent expansion/survival advantage of
GKO relative to WT CD4+ T cells in the infected
recipients.
To determine potential mechanisms of IL-17-mediated
mortality, IL-17-dependent chemokines and matrix
metalloproteinases (MMPs) [45] were analyzed in
JHMV-infected SCID recipients after transfer of WT or
GKO CD4+ T cells. Similar expression of CCL2, CCL7
and CCL20 was detected comparing infected SCID con-
trols and GKO recipients; by contrast CCL2 and CCL7
were upregulated and CCL20 downregulated in recipi-
ents of WT CD4+ T cells (Figure 7A). These data suggest
Figure 5 WT CD4+ T cell co-transfer prevents GKO CD4+ T cell induced mortality. (A) Relative MHC I-Ad class II mRNA expression in the CNS
of infected SCID recipients of WT, WT/GKO or GKO CD4+ T cells determined by quantitative real-time PCR. Data represent the mean± SEM of two
independent experiments with n= 4 per experiment. Microglial MHC class II expression quantified by flow cytometry in infected SCID recipients of WT,
WT/GKO or GKO CD4+ T cells. Data represent the mean±SD of three separate experiments with n=4 per group per experiment. (B) Survival was
assessed following infection of SCID recipients of WT (n= 20), WT/GKO (n= 20) or GKO (n= 12) CD4+ T cells. Data represent four separate experiments.
(C) Control of virus replication analyzed by plaque assay in infected control, SCID recipients of WT, WT/GKO or GKO CD4+ T cells at day eight p.i. Data
represent the average (±SD) of eight mice per group combined from two independent experiments. (D) Total number of bone-marrow-derived
leukocytes (CD45hi) and neutrophils (Ly6G+) analyzed by flow cytometry at day eight p.i. in brains of infected SCID recipients of WT, WT/GKO and GKO
CD4+ T cells. Data represent the mean of twelve mice per group combined from three independent experiments.
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that in contrast to EAE, CCL2, CCL7 and CCL20 che-
mokine expression is regulated by IFN-γ rather that IL-
17 during JHMV infection. Moreover, no significant dif-
ference in CXCL2 mRNA was found comparing SCID-
infected controls and recipients of either WT or GKO
CD4+ T cells (Figure 7A), supporting CXCL1 as the
major neutrophil chemoattractant during JHMV infec-
tion. CNS infection with JHMV induces a limited
Figure 6 IFN-γ-mediated protection prevents IL-17-mediated mortality. (A) Number of CD4+ T cells in the infiltrating population and
distribution of Thy1.1 positive cells measured by flow cytometry at day eight p.i. Data represent means (±SD) of twelve mice per group
combined from three separate experiments. (B) IL-17 mRNA expression determined by quantitative real-time PCR in infected SCID recipients of
WT, WT/GKO or GKO CD4+ T cells. Data represent the mean of two experiments with n = 4 in each group per experiment. (C) Splenocytes of
immunized GKO donors cultured in the presence of JHMV with or without recombinant IFN-γ (10 ng/ml) for six days and restimulated four hours
with PMA/Ionomycin. Intracellular cytokine expression on CD4+ T cells analyzed by flow cytometry using FITC-IFN-γ, PE-IL-17 and the
corresponding isotype controls. Dot plots are representative of duplicates from two separate experiments. (D) Survival of infected SCID recipients
of WT/GKO (n = 6), WT/GKO+ anti-IFN-γ mAb (n = 8) and GKO (n = 4) CD4+ T cells assessed daily. Data are representative of two separate
experiments.
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number of MMPs, that is, MMP9, MMP3 and MMP12
[46]. As MMP9 is specifically expressed by neutrophils
[47], abundant neutrophil recruitment in the CNS of
GKO T cell recipients (whether or not treated with anti-
IL17) correlated with MMP9 expression (Figure 7B).
MMP3 and MMP12 mRNA expression were also upre-
gulated in GKO recipients compared to infected SCID
controls and WT recipients, suggesting a potential role
of these MMPs in GKO mortality by mediating tissue
destruction (Figure 7B). However, survival of GKO reci-
pients treated with anti-IL17 also expressed increased
MMP3 and MMP12 mRNA (Figure 7B), suggesting that
MMP3 and MMP12 play no role in the early mortality
of GKO recipients. Finally, to investigate a potential con-
tribution of GM-CSF to the rapid disease progression,
relative levels of GM-CSF were measured in the CNS of
SCID-infected controls, and recipients of WT and GKO
CD4+ T cells. GM-CSF mRNA expression was increased
in GKO recipients relative to controls and WT CD4+ T
cell recipients. These data were reminiscent of enhanced
GM-CSF expression by Th17 compared to Th1 cells in
EAE [27] and suggested a potentially detrimental role
during JHMV encephalomyelitis. However, the increased
survival of GKO recipients treated with anti-IL17 mAb
did not correlate with a decrease in GM-CSF expression.
These results indicate that GM-CSF expression corre-
lated with IFN-γ deficiency, but not with an IL-17
mediated feedback loop. Nevertheless, these data suggest
that IFN-γ directly affords protection from mortality by
interfering with detrimental IL-17-mediated events, dis-
tinct from those mediating EAE.
Discussion
IFN-γ and IL-17 are major effector molecules of tissue
inflammation that play opposing roles in neutrophil re-
cruitment/accumulation [4,48,49]. While their distinct
influence on disease has been demonstrated during
autoimmune-mediated neuroinflammatory responses,
the interplay between IL-17 and IFN-γ, specifically the
effects on downstream targets remain controversial. Fur-
thermore, during microbial infections, protective and
detrimental effects of IFN-γ and IL-17 depend on the
pathogen and prominent cell types affecting microbial
control [50-52]. The present study evaluated how the ab-
sence of IFN-γ secretion by CD4+ T cells contributes to
a rapid lethal outcome during viral encephalomyelitis,
without altering viral control. Early virus-induced mor-
tality in SCID recipients of GKO virus-specific memory
CD4+ T cells correlated with both IL-17 production and
extensive neutrophil accumulation in the CNS. Selective
Figure 7 Alterations in chemokines, MMPs and GM-CSF mRNA do not correlate with IL-17-mediated mortality. (A) mRNA expression
analyzed in the CNS of naïve mice, infected control mice, and SCID recipients of WT or GKO CD4+ T cells at day eight p.i. Data represent the
mean (±SEM) of four individual mice per group (B) MMP9, MMP3, MMP12 and GM-CSF mRNA expression measured in the CNS of naïve, controls,
infected SCID recipients of WT, GKO or GKO+ anti-IL-17 CD4+ T cells at day eight p.i.. Data are representative of the mean (±SEM) of four
individual mice per group.
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blockade of either neutrophils or IL-17 demonstrated that
early mortality did not correlate with CNS neutrophil re-
cruitment, but rather with IL-17. This was confirmed by
the prolonged survival of recipients of anti-IFN-γ mAb-
treated WT recipients, which were characterized by exten-
sive neutrophil inflammation, but an absence of IL-17.
Neutrophil-independent pathogenic effects of IL-17 in
the JHMV model contrast with non-CNS viral infectious
models including the influenza virus and herpes simplex
virus-1 infections, which attribute Th17 cell-mediated
pathogenesis to neutrophil attraction [12,14]. However,
neutrophil depletion following severe influenza virus in-
fection also suggests that neutrophils play a protective,
rather than a deleterious role [53]. Our data also con-
trast with the deleterious role of neutrophils during EAE
[49,54]. Adoptive transfer of Th17 cells leads to exces-
sive CNS neutrophil migration after EAE induction,
while impaired neutrophil recruitment restrains leukocyte
access into the CNS [49], indicating a prominent role of
neutrophils in disrupting the blood-brain barrier. How-
ever, in contrast to EAE, neutrophils are not essential for
the loss of blood-brain barrier integrity following sublethal
JHMV infection [55]. By contrast, JHMV-induced enceph-
alomyelitis demonstrates that IFN-γ plays a more promin-
ent role than IL-17 in regulating CNS neutrophil
recruitment and/or retention by downregulating ELR+
neutrophil chemokine expression. Increased neutrophils
correlated with high CXCL1 expression in the CNS of
both IFN-γ-depleted WT recipients lacking IL-17, as well
as in GKO recipients treated with anti-IL-17 Ab. More-
over, neutrophil infiltration was reduced by co-transfer of
WT and GKO CD4+ T cells, despite sustained IL-17 ex-
pression in the CNS. These results are consistent with
early studies identifying IFN-γ as a critical factor regulat-
ing CNS neutrophil infiltration [4], as well as recent obser-
vations implicating IFN-γ as a dominant molecule
controlling CNS inflammation [26].
Despite evidence implicating IL-17 as a pathogenic
mediator, independent of neutrophils, the mechanism(s)
involved in IL-17-induced mortality of JHMV-infected
mice remain unclear. Identical viral burden at day eight
p.i. in all recipients [31] indicated that IL-17 does not
alter control of virus replication, in contrast to its role in
facilitating viral persistence following Theiler’s murine
encephalomyelitis virus infection [15]. Sustained Ag in-
dependent interaction between Th17 and neuronal cells
during EAE correlated with increased neuronal damage
due to IL-17-mediated neurotoxicity [25]. Increased gray
matter infection, especially in neuronal cells, is asso-
ciated with premature death following JHMV infection
of mice deficient in innate immune components [56]. In
addition, there is a preferential distribution of CD4+ T
cells in the gray matter of GKO recipients compared to
WT recipients [31], suggesting the possibility that in
absence of IFN-γ, IL-17-secreting CD4+ T cells localize
proximal to uninfected neurons, contributing to neur-
onal dysfunction and premature death. However, few
neurons are infected early during JHMV pathogenesis in
SCID mice and the types of infected cells were similar in
all groups, suggesting no alteration in viral tropism [31].
In addition, no differential neuronal loss was found com-
paring GKO and WT recipients [31]. Similarly, increased
expression of GM-CSF in GKO recipients compared to
the WT counterparts suggested that GM-CSF might also
contribute to disease outcome following JHMV infec-
tion. GM-CSF was implicated as a pathogenic effector
molecule secreted by Th17 cells during EAE [27,28].
However, the survival of GKO recipients treated with
anti-IL17 did not correlate with a decrease in GM-CSF
expression. Although GM-CSF expression is reduced by
IFN-γ [27], the data do not support a pathogenic role of
GM-CSF in early mortality of JHMV-infected GKO
recipients.
IL-17 mRNA expression in GKO CD4+ T cell recipients
suggested Th17 cells as the primary mediators of disease.
Nevertheless, IL-17 can also be produced by neutrophils,
γδ T cells, NK and CD8+ T cells [57,58]. A deleterious
contribution of neutrophil-derived IL-17, suggested dur-
ing kidney ischemia-reperfusion [39], was ruled out by the
inability of neutrophil-depletion to rescue mice from early
death, as well as the absence of IL-17 mRNA in WT reci-
pients treated with anti-IFN-γ, despite high CNS neutro-
phil infiltration. IL-17 production by CD4+ T cells derived
from immunized GKO donors prior to transfer supports
GKO CD4+ T cells as the primary source of IL-17. More-
over, stimulation of WT donor CD4+ T cells strongly
induced IFN-γ, but not IL-17, indicating that virus-
specific Th17 cells only differentiate in the absence of
IFN-γ. These results support previous observations of a
minor, if any, role of Th17 cells in the pathogenesis of
JHMV-infected immunocompetent WT mice [38] and
corroborate the inhibitory function of IFN-γ on Th17 dif-
ferentiation during T cell priming [59]. However, our data
are novel in demonstrating that memory GKO CD4+ T
cells are committed in their ability to produce IL-17 when
restimulated in the recipient host, even in the presence of
IFN-γ. Although unanticipated, this finding was confirmed
by the inability of IFN-γ to downregulate IL-17 produc-
tion in GKO donor cells in vitro, as well as on in vitro-dif-
ferentiated mature Th17 cells [15]. Similarly, the IL-27
suppressive function on Th17 differentiation from naïve
CD4+ T cells could not be reproduced on memory Th17
cells [60], supporting the stability of committed Th17
cells. Importantly, the prolonged survival of co-transferred
recipients, despite sustained CNS IL-17 expression, sug-
gests that IFN-γ overcomes the deleterious effects of IL-
17. However, the mechanisms by which IFN-γ overrides
IL-17 function remain unclear. In EAE, IL-17 exerts
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detrimental effects via signaling in resident CNS cells,
with astrocytes implicated as major targets [45]. However,
Th17 cell localization proximal to neurons also implicates
potential dysregulation of neuronal function [25]. Respon-
siveness of both cell types to IFN-γ [61,62] suggests IFN-γ
may counteract signaling molecules downstream of the
IL-17R.
Conclusions
This study demonstrates that IL-17, in the absence of
IFN-γ, can accelerate mortality during viral encephalo-
myelitis by a mechanism independent of the magnitude
of CNS neutrophil infiltration and reversible by IFN-γ.
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